Skip to main content

Table 3 QoL score and VAS

From: The efficacy of alpha-1A blocker (tamsulosin), antimuscarinic (solifenacin) and their combination in the management of double-J stent-related lower urinary tract symptoms: a randomized controlled study

 

Control

Tamsulosin

Solifenacin

Combined therapy

P-value

Median (Range)

Median (Range)

Median (Range)

Median (Range)

QoL

Pre-insertion

0 (0–0)

0 (0–1)

0 (0–1)

0 (0–1)

0.31

After 2 weeks

5a,b,c (4–6)

3a,d (1–5)

3b,e (1–5)

2c,d,e (1–3)

< 0.001

VAS

Pre-insertion

1 (0–2)

1 (0–2)

0 (0–1)

1 (0–2)

0.11

After 2 weeks

7a,b,c (4–9)

4a,d (3–6)

4b,e (2–5)

3c,d,e (1–5)

0.021

  1. Similar letters (a, b, c, d, e) indicate significant difference
  2. QoL Quality of life; VAS visual analog scale